Reach Us +44-1647-403003
First In Human Report Of Intravenous Infusion Of Metavec (synthetic Bacteriophage Delivering Genetic Cargo) In A Patient With Metastatic Ovarian Cancer | 83478
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Share This Page

First in human report of intravenous infusion of Metavec (synthetic bacteriophage delivering genetic cargo) in a patient with metastatic ovarian cancer

2nd Global Summit on Oncology & Cancer

Keith Potent, Armand Sinclair

Monash University, Australia Novother Cancer Research, New Zealand

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956-C1-123

We present a first in human case of a 50 year-old patient with end-stage metastatic ovarian cancer infused with a novel, intravenously administered, synthetically engineered bacteriophage-based gene therapy (Metavec) for metastatic solid malignancies. Compared to mammalian virus-based delivery vehicles, bacteriophage-based vectors bring many preferable features for treatment in humans. Their genomes have been extensively sequenced and with modern technologies, they are relatively malleable allowing them to be extensively modified. Unlike mammalian viruses, bacteriophages are not natural pathogens to humans yet their capsid can have equivocal cargo carrying capacity. To the authors’ best knowledge, no other bacteriophage-based applications have succeeded with intravenous administration. This advance in nanotechnology and novel approach could revolutionize medical care. The patient we discuss received a dose-escalating regime up to 1x1011 particles per dose, three times a week for three weeks. The infusions were very well tolerated. Symptoms include nausea, low-grade fever and also discomfort in areas where larger tumors were present. Post-infusion investigations included serum biochemistry, serum tumor markers and computed tomography. The paradigm shift, results and discussion will be presented.

Potent is currently a PhD candidate in Translational Research at Monash University. After completed undergraduate degrees in Mathematics and Chemistry, Potent completed his medical degree. He is a practising doctor in Queensland. Today is presenting a small part of a significant body of research conducted by Armand Sinclair, Novother Cancer Research.
Email:[email protected]

Relevant Topics